Study summary
The first drug for bronchiectasis cut flare-ups by about a fifth
0.79rate ratio for flare-ups vs placebo (10 mg)
What was tested
Brensocatib, a once-daily pill that blocks DPP-1, an enzyme that arms neutrophils (inflammatory white cells) in the airways, at 10 mg or 25 mg, against placebo.
What they found
- Yearly flare-up rate: 1.02 (10 mg) and 1.04 (25 mg) vs 1.29 with placebo (rate ratio 0.79 and 0.81).
- 48.5% stayed flare-free for a year vs 40.3% with placebo.
- Lung function declined less at 25 mg; skin thickening (hyperkeratosis) was more common.
What it means
The first approved treatment for non-cystic fibrosis bronchiectasis, targeting the inflammation behind it.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.